Protagonist Therapeutics (NASDAQ:PTGX) and Equillium (NASDAQ:EQ) Financial Survey

Protagonist Therapeutics (NASDAQ:PTGX) and Equillium (NASDAQ:EQ) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Volatility & Risk

Protagonist Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Equillium has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500.

Valuation & Earnings

This table compares Protagonist Therapeutics and Equillium”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02 million	197.20	-$130.15 million	$1.03	136.16
Equillium	$41.10 million	2.18	-$22.40 million	($0.20)	-7.05

Equillium has lower revenue, but higher earnings than Protagonist Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Protagonist Therapeutics and Equillium’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Equillium	N/A	-41.15%	-38.29%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Protagonist Therapeutics and Equillium, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	1	15	1	3.00
Equillium	1	1	7	2	2.91

Protagonist Therapeutics currently has a consensus target price of $163.27, indicating a potential upside of 16.42%. Equillium has a consensus target price of $7.57, indicating a potential upside of 436.98%. Given Equillium’s higher probable upside, analysts plainly believe Equillium is more favorable than Protagonist Therapeutics.

Summary

Protagonist Therapeutics beats Equillium on 10 of the 15 factors compared between the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.